Innate Pharma Advances Cancer Immunotherapy with Innovative Research and Strategic Collaborations

Innate Pharma's Commitment to Cancer Immunotherapy Development

Innate Pharma SA, a clinical-stage biotechnology firm based in Marseille, France, underscores its commitment to advancing cancer immunotherapy through its innovative research and development efforts. The company announces its compliance with French regulations by revealing its total number of shares outstanding and voting rights as of December 31, 2024. With 83,830,336 ordinary shares, in addition to 6,494 Preferred Shares from 2016 and 7,581 from 2017, Innate Pharma reports a total of 84,585,576 theoretical voting rights. This figure includes shares with suspended voting rights, while the total number of exercisable voting rights is calculated at 84,567,001, excluding treasury shares.

Central to Innate Pharma's strategy is its proprietary ANKET® platform, which focuses on developing multi-specific NK Cell Engagers, alongside a robust portfolio that includes Antibody Drug Conjugates (ADCs) and monoclonal antibodies. The company actively pursues several drug candidates that target various tumor types, with notable candidates such as IPH4502—a differentiated ADC aimed at solid tumors—and lacutamab, an anti-KIR3DL2 monoclonal antibody specifically designed for cutaneous T cell lymphomas. These innovative therapeutic approaches exemplify Innate Pharma's dedication to addressing unmet medical needs in oncology and enhancing patient outcomes.

Furthermore, Innate Pharma's collaboration with major biopharmaceutical companies, including AstraZeneca and Sanofi, enriches its research capabilities and accelerates the development of promising therapies. One of the key collaborations involves the development of monalizumab, an anti-NKG2A monoclonal antibody, for non-small cell lung cancer in partnership with AstraZeneca. This strategic alliance not only amplifies Innate Pharma's research efforts but also positions the company favorably within the competitive landscape of cancer immunotherapy, highlighting its role as a significant player in the biopharmaceutical sector.

In addition to its robust drug development pipeline, Innate Pharma maintains a strong presence in the international market, being publicly traded on both Euronext Paris and Nasdaq. This dual listing enhances its visibility and provides access to a broader base of investors interested in innovative healthcare solutions. For further insights into Innate Pharma's cutting-edge work in cancer immunotherapy, interested parties can visit their website or follow the company on social media platforms.